| Modeling of SARS-CoV-2 treatment effects for informed drug repurposing C Kern, V Schöning, C Chaccour, F Hammann Frontiers in Pharmacology 12, 625678, 2021 | 17 | 2021 |
| Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes C Kern, P Müller, C Chaccour, ME Liechti, F Hammann, U Duthaler Malaria journal 22 (1), 194, 2023 | 10 | 2023 |
| Effectiveness of antiviral therapy in highly-transmissible variants of SARS-CoV-2: a modeling and simulation study V Schöning, C Kern, C Chaccour, F Hammann Frontiers in Pharmacology, 218, 2022 | 10 | 2022 |
| Mosquitocidal efficacy and pharmacokinetics of single-dose ivermectin versus three-day dose regimen for malaria vector control compared with albendazole and no treatment: An … Y Kamau, M Tuwei, C Wanjiku, K Ominde, M Ngama, J Karisa, L Babu, ... International Journal of Infectious Diseases 148, 107236, 2024 | 1 | 2024 |
| Nicotine does not affect SARS-CoV-2 in-host viral kinetics in a modeling and simulation study C Kern, CM Vonwyl, V Schoning, E Liakoni, F Hammann CLINICAL TOXICOLOGY 59 (6), 594-595, 2021 | | 2021 |
| Highly-transmissible Variants of SARS-CoV-2 May Be More Susceptible to Drug Therapy Than Wild Type Strains V Schöning, C Kern, C Chaccour, F Hammann | | 2021 |
| Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing. Front. Pharmacol. 12: 625678. doi: 10.3389/fphar. 2021.625678 C Kern, V Schöning, C Chaccour, F Hammann Frontiers in Pharmacology| www. frontiersin. org 12, 2021 | | 2021 |
| Modeling changes in SARS-CoV-2 variants within-host transmissibility on antiviral drug effect C Kern, V Schöning, C Chaccour, F Hammann PAGE 29 (2021) Abstr 9737 [www.page-meeting.org/?abstract=9737], 2021 | | 2021 |
Felix HammannUniversity Hospital BernVerified email at med.unibe.ch